EUVIMEDOpdag EUVIMED
Crossref

Sculponeatin A induces mitochondrial dysfunction in non‐small cell lung cancer through WWP2‐mediated degradation of mitochondrial STAT3

Fang Wan, Chen Qian, Xuewen Liu, Yifan Zhong, Wenkang Peng, Liang Zhang, Xiangrong Zhan, Yongtong Huang, Chengyu Zhang, Jiu Wang, Yuan Si, Ying Liu

British Journal of Pharmacology · 2025-06 · 182 (12) · 2662-2681

DOI: 10.1111/bph.17460 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2025-02-24. Written by Fang Wan and 11 co-authors. Institution: Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, STAT3 Transcription Factor, Mitochondria. Cited 12 times so far (Crossref); 45 references. Funded by: National Natural Science Foundation of China, Foundation of Hubei Provincial Department of Science and Technology, Advantages Discipline Group Project in Higher Education of Hubei Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose The phosphorylation of signal transducer and activator of transcription 3 (STAT3) monomer at S727 promotes its mitochondrial localisation and regulates mitochondrial function, thus exerting a protective effect on tumour cells. However, no inhibitor drugs targeting mitochondrial STAT3 (mitoSTAT3) or S727‐STAT3 phosphorylation have been identified. Here, we report a novel diterpenoid extracted from Isodon sculponeatus , sculponeatin A (sptA), induces mitochondrial dysfunction in non‐small cell lung cancer (NSCLC) by targeting mitoSTAT3 degradation. Experimental Approach xCELLigence real‐time cell analysis assay and high‐content analysis were performed to measure cytotoxicity. Mitochondrial function was assessed by transmission electron microscopy, mitochondrial permeability transition pore opening and Seahorse cellular flux assays. The effects of sptA on the upstream signalling pathway of mitochondrial dysfunction were measured by Western blot, gene alterations and other approaches. Immunofluorescence and live cell imaging were performed to visualise the expression and position of mitoSTAT3. Nude mice and zebrafish were modelled with subcutaneous xenografts. Pharmacokinetics of sptA were examined in rats. Drug toxicity was evaluated in zebrafish. Key Results sptA inhibited mitochondrial respiration in NSCLC cells. sptA induced mitochondrial dysfunction by promoting the degradation of mitoSTAT3. sptA promoted WW domain containing E3 ubiquitin protein ligase 2 (WWP2)‐mediated ubiquitination and degradation of mitoSTAT3 through direct binding. sptA inhibited tumour growth in vivo. Evaluation of drug toxicity in zebrafish showed that overdose of sptA may cause heart damage. Conclusions and Implications These findings suggest that pharmacological targeting the degradation of mitoSTAT3 by sptA may provide therapeutic benefits against NSCLC.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSTAT3 Transcription FactorMitochondriaUbiquitin-Protein LigasesDiterpenesAnimalsHumansMice, NudeZebrafishMiceRatsMaleRats, Sprague-DawleyProteolysisCell Line, Tumor

Author keywords

WWP2mitoSTAT3mitochondrial dysfunctionnon‐small cell lung cancersculponeatin A

Substances

STAT3 Transcription FactorUbiquitin-Protein LigasesDiterpenesSTAT3 protein, human

Authors and institutions

  • Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China.
  • Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China.
  • Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, China.
  • Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan, China.

Funding

  • National Natural Science Foundation of China
  • Foundation of Hubei Provincial Department of Science and Technology
  • Advantages Discipline Group Project in Higher Education of Hubei Province
  • Natural Science Foundation of Hubei Provincial Department of Education
  • National Training Program of Innovation and Entrepreneurship for Undergraduates

Cite

APA

Wan, F., Qian, C., Liu, X., Zhong, Y., Peng, W., Zhang, L., Zhan, X., Huang, Y., Zhang, C., Wang, J., Si, Y., & Liu, Y. (2025). Sculponeatin A induces mitochondrial dysfunction in non‐small cell lung cancer through WWP2‐mediated degradation of mitochondrial STAT3. British Journal of Pharmacology, 182(12), 2662-2681. https://doi.org/10.1111/bph.17460

Vancouver

Wan F, Qian C, Liu X, Zhong Y, Peng W, Zhang L, et al. Sculponeatin A induces mitochondrial dysfunction in non‐small cell lung cancer through WWP2‐mediated degradation of mitochondrial STAT3. British Journal of Pharmacology. 2025;182(12):2662-2681. doi:10.1111/bph.17460

BibTeX
@article{Wan2025,
  author = {Wan, Fang and Qian, Chen and Liu, Xuewen and Zhong, Yifan and Peng, Wenkang and Zhang, Liang and Zhan, Xiangrong and Huang, Yongtong and Zhang, Chengyu and Wang, Jiu and Si, Yuan and Liu, Ying},
  title = {Sculponeatin A induces mitochondrial dysfunction in non‐small cell lung cancer through WWP2‐mediated degradation of mitochondrial STAT3},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {12},
  pages = {2662--2681},
  doi = {10.1111/bph.17460}
}
Start for free →